Taxiarchis Kourelis
Overview
Explore the profile of Taxiarchis Kourelis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
1285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dingli S, Rothweiler P, Binder M, Cook J, Gertz M, Hayman S, et al.
Leukemia
. 2025 Mar;
PMID: 40044958
No abstract available.
2.
Rees M, Muchtar E, Atallah-Yunes S, Dasari S, Leung N, Gertz M, et al.
Amyloid
. 2025 Feb;
:1-3.
PMID: 39972595
No abstract available.
3.
Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, et al.
Blood Cancer J
. 2025 Feb;
15(1):20.
PMID: 39966346
Risk stratification models based on cytogenetics and disease burden help identify high-risk patients with newly diagnosed multiple myeloma (NDMM). However, some high-risk patients remain undetected. This study evaluated the prognostic...
4.
Netzel B, Charlesworth M, Johnson K, French A, Dispenzieri A, Maleszewski J, et al.
Amyloid
. 2025 Jan;
32(1):72-80.
PMID: 39773246
Background: Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque...
5.
Lee K, Kourelis T, Tschautscher M, Warsame R, Buadi F, Gertz M, et al.
Leukemia
. 2024 Dec;
39(3):703-709.
PMID: 39681639
Cause of death (COD) in POEMS (polyneuropathy, organomegaly, endocrinopathies, monoclonal protein and skin changes) syndrome is not well described. We investigated COD in patients with POEMS syndrome treated at Mayo...
6.
Abdallah N, Bohra A, Mammadzadeh A, Buadi F, Buadi F, Kapoor P, et al.
Blood Adv
. 2024 Dec;
9(4):884-892.
PMID: 39637309
Patient-reported outcomes (PROs) are associated with treatment outcomes in multiple myeloma (MM) in the clinical trial setting. However, most PRO tools are time consuming, which hinders use in routine practice....
7.
Vaxman I, Kumar S, Cohen I, Simony S, Shimony S, Dispenzieri A, et al.
Br J Haematol
. 2024 Nov;
206(2):607-614.
PMID: 39613336
In 2014, the International Myeloma Working Group (IMWG) updated the criteria for diagnosing myeloma and added three additional criteria to the traditional Calcium elevation, Renal impairment, Anemia, Bone disease (CRAB)...
8.
Goel U, Charalampous C, Kapoor P, Binder M, Buadi F, Dingli D, et al.
Blood Adv
. 2024 Nov;
8(24):6321-6328.
PMID: 39536293
As patients with relapsed/refractory multiple myeloma (RRMM) continue to live longer, they might get exposed to most available drugs and drug classes during the disease course. For such late line...
9.
Jevremovic D, Shi M, Horna P, Otteson G, Timm M, Bennett S, et al.
Am J Hematol
. 2024 Sep;
99(12):2399-2401.
PMID: 39291868
No abstract available.
10.
Khurana A, Rosenthal A, Mohty R, Gaddam M, Bansal R, Hathcock M, et al.
Blood Cancer J
. 2024 Aug;
14(1):136.
PMID: 39134524
No abstract available.